(NASDAQ: CRBU) Caribou Biosciences's forecast annual revenue growth rate of 29.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.66%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.96%.
Caribou Biosciences's revenue in 2026 is $6,139,000.On average, 8 Wall Street analysts forecast CRBU's revenue for 2026 to be $1,156,661,858, with the lowest CRBU revenue forecast at $1,039,805,669, and the highest CRBU revenue forecast at $1,319,295,655. On average, 7 Wall Street analysts forecast CRBU's revenue for 2027 to be $1,339,129,045, with the lowest CRBU revenue forecast at $1,082,152,636, and the highest CRBU revenue forecast at $1,688,518,330.
In 2028, CRBU is forecast to generate $1,414,174,304 in revenue, with the lowest revenue forecast at $1,207,907,049 and the highest revenue forecast at $1,688,518,330.